Atara Biotherapeutics GAAP EPS of -$0.32 beats by $0.37, revenue of $3.5M beats by $0.76M

* Atara Biotherapeutics press release [https://seekingalpha.com/pr/20304068-atara-biotherapeutics-announces-third-quarter-financial-results-and-operational-progress] (ATRA [https://seekingalpha.com/symbol/ATRA]): Q3 GAAP EPS of -$0.32 beats by $0.37.
* Revenue of $3.5M (-91.3% Y/Y) beats by $0.76M.
* Cash, cash equivalents and short-term investments as of September 30, 2025, totaled $13.7 million, as compared to $22.3 million as of June 30, 2025.
* Net cash used in operating activities was $9.8 million for the third quarter 2025, as compared to $4.0 million in the same period in 2024. Net cash used in operating activities increased by $5.8 million year-over-year, primarily driven by a decrease in cash receipts from Pierre Fabre in the third quarter 2025 after the BLA acceptance milestone and a sale of tab-cel intermediates inventory were completed in the same period in 2024, this was partially offset by a decrease in operating expenses in the third quarter 2025.
* Atara reported net loss of $4.3 million, or $0.32 per share for the third quarter 2025 as compared to $21.9 million or $2.93 per share for the same period in 2024.

MORE ON ATARA BIOTHERAPEUTICS

* Seeking Alpha’s Quant Rating on Atara Biotherapeutics [https://seekingalpha.com/symbol/ATRA/ratings/quant-ratings]
* Historical earnings data for Atara Biotherapeutics [https://seekingalpha.com/symbol/ATRA/earnings]
* Financial information for Atara Biotherapeutics [https://seekingalpha.com/symbol/ATRA/income-statement]